Want to see AU:RHT full AI Analyst Report?
Top Page
Resonance Health Ltd
(Sydney:RHT)
Select Model
Select Model
Rating:66Neutral
Price Target:
AU$0.08
▲(56.00% Upside)
Action:Reiterated
Date:09/30/26
The score is driven primarily by improving financial performance (profitability rebound and strong revenue growth) but tempered by earnings/cash-flow volatility and higher leverage versus earlier years. Technicals are supportive due to a strong uptrend, yet overbought signals raise near-term pullback risk. Valuation is moderate at a 22.5 P/E with no dividend yield data to add support.
Positive Factors
Multi-year revenue scaling
Revenue increased from approximately $3.8m in 2021 to $15.8m in 2026, showing substantial commercial scaling over multiple years. This expansion suggests broader adoption of the software business and creates a larger base from which recurring or usage-linked revenue can compound.
Negative Factors
Earnings volatility
Profitability has not yet demonstrated consistency: the company moved from profit in 2024 to a sizable loss in 2025 and back to profit in 2026. Such swings make sustainable earnings harder to assess and raise the risk that future results will again diverge from the latest recovery.
Read all positive and negative factors
Positive Factors
Negative Factors
Multi-year revenue scaling
Revenue increased from approximately $3.8m in 2021 to $15.8m in 2026, showing substantial commercial scaling over multiple years. This expansion suggests broader adoption of the software business and creates a larger base from which recurring or usage-linked revenue can compound.
Read all positive factors
Resonance Health Ltd (RHT) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$32.44M
Dividend YieldN/A
Average Volume (3M)412.96K
Price to Earnings (P/E)22.2
Beta (1Y)1.72
Revenue Growth42.25%
EPS GrowthN/A
CountryAU
Employees18
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)<0.01
Shares Outstanding477,120,240
10 Day Avg. Volume538,258
30 Day Avg. Volume412,957
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)1.87
Price to Sales (P/S)1.32
P/FCF Ratio7.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Resonance Health Ltd Business Overview & Revenue Model
Company Description
Resonance Health Limited is a global provider of healthcare technology and services, specializing in the design, development, and production of software-as-medical devices. The company serves markets across the Asia Pacific, Americas, Europe, Midd...
How the Company Makes Money
Resonance Health generates revenue primarily by commercialising its medical imaging software and related services. Key revenue streams include: (1) Software licensing and subscriptions: income from licensing its imaging-analysis software to hospit...
Resonance Health Ltd Financial Statement Overview
Summary
Income Statement
71
Positive
Balance Sheet
63
Positive
Cash Flow
68
Positive
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 15.75M | 11.07M | 8.59M | 4.40M | 3.83M |
| Gross Profit | 14.80M | 11.07M | 8.59M | 4.40M | 3.83M |
| EBITDA | 2.48M | -1.41M | -382.00K | -827.69K | -1.34M |
| Net Income | 1.51M | -1.73M | 169.30K | -780.00K | -1.14M |
Balance Sheet | |||||
| Total Assets | 18.74M | 17.89M | 20.28M | 10.98M | 11.69M |
| Cash, Cash Equivalents and Short-Term Investments | 4.85M | 2.98M | 6.85M | 6.36M | 6.78M |
| Total Debt | 3.81M | 3.80M | 3.70M | 272.94K | 268.22K |
| Total Liabilities | 7.63M | 8.50M | 9.35M | 1.05M | 995.58K |
| Stockholders Equity | 11.11M | 9.39M | 10.93M | 9.94M | 10.69M |
Cash Flow | |||||
| Free Cash Flow | 2.79M | 805.39K | 1.01M | -624.93K | -1.42M |
| Operating Cash Flow | 2.88M | 1.25M | 1.39M | -157.03K | -712.67K |
| Investing Cash Flow | -300.53K | -4.52M | -3.94M | -467.90K | -704.00K |
| Financing Cash Flow | -597.54K | -649.26K | 3.01M | -81.97K | -107.11K |
Resonance Health Ltd Technical Analysis
Positive
0.05
Price Trends
0.06
Positive
0.05
Positive
0.05
Positive
Market Momentum
<0.01
Negative
80.12
Negative
65.08
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:RHT, the sentiment is Positive. The current price of 0.05 is below the 20-day moving average (MA) of 0.06, below the 50-day MA of 0.06, and above the 200-day MA of 0.05, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 80.12 is Negative, neither overbought nor oversold. The STOCH value of 65.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:RHT.
Resonance Health Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | AU$16.83B | 61.57 | 63.19% | 0.44% | 22.87% | 130.30% | |
66 Neutral | AU$32.44M | 22.19 | 13.72% | ― | 42.25% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | AU$29.53M | -1.59 | -58.13% | ― | 2.08% | -195.31% | |
47 Neutral | AU$54.05M | -6.05 | -24.29% | ― | -17.35% | -47.29% | |
44 Neutral | AU$60.33M | -9.11 | -57.06% | ― | 603.32% | 10.57% | |
43 Neutral | AU$560.58M | -21.26 | -30.04% | ― | <0.01% | 2.08% |
* Healthcare Sector Average
AU:RHT
Resonance Health Ltd
0.07
0.03
73.17%
AU:PME
Pro Medicus Limited
156.38
-156.09
-49.95%
AU:M7T
Mach7 Technologies
0.23
-0.08
-26.98%
AU:BMT
Beamtree Holdings Ltd
0.10
-0.12
-54.55%
AU:SHG
Singular Health Group Ltd
0.19
-0.10
-33.93%
AU:AYA
Artrya Limited
3.70
1.30
54.17%
Resonance Health Ltd Corporate Events
Resonance Health Sets AGM Date and Board Nomination Deadline
Sep 29, 2026
Resonance Health Ltd has scheduled its next Annual General Meeting for 19 November 2026, with formal meeting materials to be circulated to shareholders and published via the ASX and the company’s investor website in due course. The company h...
Resonance Health Strikes Global Imaging Alliance with Image Analysis Group
Sep 16, 2026
Resonance Health has signed a Strategic Alliance and Master Services Agreement with London-based Image Analysis Group, integrating its quantitative MRI endpoints into IAG’s global imaging clinical research platform. The deal makes Resonance&...
Resonance Health Files 2026 Corporate Governance Statement with ASX
Aug 31, 2026
Resonance Health Limited has lodged its Appendix 4G and corporate governance statement with the ASX for the financial year ended 30 June 2026, confirming compliance with ASX Listing Rules on governance disclosure. The documents, approved by the bo...
Resonance Health Returns to Profit on Record Revenue and Strong Trial Pipeline
Aug 28, 2026
Resonance Health reported a 42% rise in full-year revenue to $15.8 million and returned to profitability with a $1.5 million net profit after tax for the year to 30 June 2026. Normalised EBITDA jumped 83% to $2.6 million at a 16% margin, with all ...
Resonance Health swings to profit on 42% revenue surge
Aug 27, 2026
Resonance Health Limited reported a strong turnaround for the year ended 30 June 2026, with revenues from ordinary activities rising 42% to $15.75 million and net profit after tax of $1.51 million, compared with a loss of $1.73 million in the prio...
Resonance Health to Host Investor Webinar on FY26 Results
Aug 19, 2026
Resonance Health will release its full-year financial results for the period to 30 June 2026 on or before 28 August 2026 via the ASX platform. The company’s chief executive officer and chief financial officer will then host a live, interacti...
Resonance Health Ends ASX Quarterly Cash Flow Reporting After Strong FY26 Performance
Aug 12, 2026
Resonance Health Ltd, an Australian healthcare technology firm, specialises in AI‑enabled, MRI‑based Software‑as‑Medical Devices used globally for quantitative assessments of liver and cardiac conditions. Its solutions supp...
Resonance Health Director Increases Indirect Shareholding Via Off-Market Trade
Jul 15, 2026
Resonance Health Limited has reported a change in director Simon Panton’s indirect interests, with an associated entity controlled by his wife acquiring 1,640,824 ordinary fully paid shares for $73,837 in an off-market trade. Following the t...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.